On May 13, 2024, at the 33rd European Congress on Obesity (ECO) held in Istanbul, Türkiye, groundbreaking Phase 3b trial…
Read More

On May 13, 2024, at the 33rd European Congress on Obesity (ECO) held in Istanbul, Türkiye, groundbreaking Phase 3b trial…
Read More
The pharmaceutical industry finds itself at a critical juncture, grappling with escalating costs, protracted timelines, and persistently high failure rates…
Read More
A groundbreaking study involving over 23andMe customers has identified genetic variations in two key genes that significantly influence both the…
Read More
The pharmaceutical industry grapples with an intractable challenge: the escalating cost and protracted timelines of drug development, coupled with persistently…
Read More
A comprehensive review of 17 clinical trials by the esteemed Cochrane organization has cast doubt on the clinically meaningful benefits…
Read More
A large-scale study analyzing the genetic data of 23andMe customers has identified specific variants in two genes that significantly influence…
Read More
The pharmaceutical industry grapples with an intractable problem: the escalating cost and protracted timelines of drug development, coupled with persistently…
Read More
The pharmaceutical industry, perpetually navigating a landscape of escalating costs and protracted timelines, faces a critical juncture where innovation is…
Read More
New Orleans, LA – A groundbreaking Bayesian network meta-analysis presented at the American College of Cardiology (ACC) 75th Annual Scientific…
Read More
The pharmaceutical industry faces an escalating crisis marked by soaring costs, protracted timelines, and persistently low success rates in bringing…
Read More